Lexaria Bioscience Corp (LEXX) Stock Price, Quote & News

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is...

Industry: Biotechnology

Sector: Healthcare

Phone: 250 765 6424

Website: lexariabioscience.com

Address:

740 McCurdy Road, Suite 100, Kelowna, Canada

The_Wealth_Maker May. 19 at 6:44 PM

$LEXX 'The only thing I know is that I know nothing.' - Socrate -

0 · Reply

Boston7452 May. 19 at 6:13 PM

$LEXX I believe Lexx was recommended to me because they planned to do the same thing here that happened at Sintx. Hoping I would tout the technology while they shorted this to a reverse split as I touted the tech there. Big difference was I wasnt aware that cost basis harvesting was really a thing until they recommended TRNR to me. I never invested in TRNR because I could see what it was from really early. This one was a bit harder to recognize because there is legit business going on with sold tech. TRNR is ran like a complete scam. Sintx has great tech but previous mgmt tried to sell the company cheap for the benefit of a few.

0 · Reply

Bigfin May. 19 at 6:04 PM

$LEXX Will the current studies scheduled to start dosing in mid-June have results before the nasdaq deadline in August? I sure hope so as it seems only good news from these studies will save us from a reverse split.

0 · Reply

focafoca99 May. 19 at 4:42 PM

$LEXX eyes mid-June dosing after IRB approval for its new oral semaglutide pilot study.

0 · Reply

Boston7452 May. 19 at 4:25 PM

$LEXX There is nothing genius about cost basis harvesting. Its something that the SEC should put an end to. High net individuals and funds are encouraged to force companies to reverse split to reduce their tax liability. Some companies management profit from this like over at TRNR. I dont need to make it up, i witnessed it. My warrants for another company cost basis skyrocketed from just over 10k original cost to in the tens of millions because I held through two very large reverse splits. Intracoastal, one of the anson family of funds here, was one of the funds involved in at least one of those RS.

1 · Reply

Boston7452 May. 19 at 4:10 PM

$LEXX Lex allows management to hedge as it has no policy against it, per the 10k. Warrants remain the same post reverse split. Meaning if there is a 10:1 RS and a warrant holder had 1m warrants, they still hold 1m warrants post RS. What actually adjusts is the number of shares created per warrant. So while the holder still had 1m warrants those warrants would convert into 100,000 shares instead of 1m. To compensate for this the cost basis of the warrant is increase 10x. So those 1m warrants with an original cost basis of 1m now have a cost basis of 10m. Thus an increase in tax write off of 9m. Wash trading can impact this.

1 · Reply

Makingmillions192 May. 19 at 3:26 PM

$LEXX Taking a bow like LongLexx - not worth anyone’s time debating with or listening to shorts like Boston who make up fallacies about the stock all day. Goodluck all. I’ll come back when mgmt shuts up Boston.

1 · Reply

Makingmillions192 May. 19 at 3:19 PM

$LEXX LMFAO the message-board fan fiction is hilarious 😆 Boston is inventing “mechanics” to sound like a genius. In reality, every single theory is literal bullshit. Executives can't magically "hedge" their own equity to profit as the stock drops. Section 16 insiders face strict SEC bans on short-selling or buying puts on their own company. A reverse split doesn't delete warrants or hand funds a giant tax offset. Warrants are structurally adjusted by the split ratio (e.g., 10 old warrants become 1 new warrant with 10x the strike price). The cost basis remains exactly the same. Therefore, there is no “cleaning” of a cap table. Chris Bunka disposing of shares isn't an RS signal; it’s an executive returning shares to the corp treasury for no tax benefit. He could have sold the shares for a gain but he didn’t. This isn't a grand tax conspiracy between management and short funds. It's just a heavily diluted, cash-burning micro-cap bleeding in a total news vacuum.

0 · Reply

hovian May. 19 at 2:51 PM

$LEXX cant belive someone can get lexx shares at 55 cents...

0 · Reply

hovian May. 19 at 2:48 PM

$LEXX is this sp real? men I cant belive... how many shares have Bunka?

0 · Reply

Lexaria Bioscience announces ethics approval for Human Pilot Study 7

NVO

May 7, 2026, 9:25 AM EDT - 12 days ago

Lexaria Bioscience Releases Second Episode of Investor Video Series

2026-05-05T13:24:25.000Z - 14 days ago

Lexaria Bioscience provides update on Human Pilot Study #7

NVO

May 5, 2026, 9:10 AM EDT - 14 days ago

Lexaria Updates Progress on Human Study #7

May 1, 2026, 9:25 AM EDT - 18 days ago

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

2026-04-29T13:16:24.000Z - 20 days ago

Lexaria Bioscience extends material transfer agreement with pharma company

Apr 29, 2026, 9:10 AM EDT - 20 days ago

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

2026-04-23T13:23:01.000Z - 26 days ago

Lexaria Bioscience launches new study to examine next-gen GLP-1 drugs

Apr 23, 2026, 9:05 AM EDT - 26 days ago

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

2026-04-21T15:02:42.000Z - 4 weeks ago

Lexaria Bioscience provides update on GLP-1 oral pill market

Apr 21, 2026, 9:10 AM EDT - 4 weeks ago

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

2026-04-15T13:24:10.000Z - 4 weeks ago

Lexaria Bioscience engages CRO for 2026 GLP-1-A26-1 study

Apr 15, 2026, 9:10 AM EDT - 4 weeks ago

Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

2026-04-07T13:40:33.000Z - 6 weeks ago

Lexaria Bioscience ‘applauds’ Eli Lilly’s Foundayo drug approval

LLY

Apr 7, 2026, 9:10 AM EDT - 6 weeks ago

Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval

2026-04-01T13:26:48.000Z - 6 weeks ago

Lexaria Bioscience to begin new human clinical study in GLP-1

Apr 1, 2026, 9:20 AM EDT - 6 weeks ago

Lexaria to Begin New Human Clinical Study in GLP-1

2026-03-26T13:25:26.000Z - 7 weeks ago

Lexaria receives five new patents, including two for diabetes treatment

Mar 26, 2026, 9:20 AM EDT - 7 weeks ago

Lexaria's Robust Patent Portfolio Continues to Grow

Mar 24, 2026, 9:15 AM EDT - 2 months ago

Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

2026-03-04T14:39:22.000Z - 2 months ago

Lexaria Bioscience announces 2026 R&D plans

Mar 4, 2026, 9:25 AM EST - 2 months ago

Lexaria Announces New R&D Plans for 2026

2026-02-05T14:25:56.000Z - 3 months ago

Lexaria announces final results from GLP-1-H25-5 study

Feb 5, 2026, 9:15 AM EST - 3 months ago

Lexaria Announces Positive Final Results From Human Pilot Study #5

2026-01-22T14:25:16.000Z - 4 months ago

Lexaria Bioscience awarded six additional patents

Jan 22, 2026, 9:20 AM EST - 4 months ago

Lexaria Awarded Six Additional Patents

2026-01-12T14:50:08.000Z - 4 months ago

Lexaria CEO says ‘closer to a commercial breakthrough than ever before’

Jan 12, 2026, 9:10 AM EST - 4 months ago

Lexaria Releases Annual Letter from the CEO

2025-12-30T14:25:09.000Z - 5 months ago

Lexaria releases additional results from Phase 1b study GLP-1-H24-4

Dec 30, 2025, 9:20 AM EST - 5 months ago

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

2025-12-29T22:25:07.000Z - 5 months ago

Lexaria Bioscience files to sell 2.75M shares of common stock for holders

2025-12-23T14:35:06.000Z - 5 months ago

Lexaria Bioscience achieves primary endpoint in Phase 1b study GLP-1-H24-4

Dec 23, 2025, 9:29 AM EST - 5 months ago

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Dec 16, 2025, 4:00 PM EST - 5 months ago

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2025-12-15T13:21:02.000Z - 5 months ago

Lexaria Bioscience prices 2.66M share at the market offering at $1.315

Dec 15, 2025, 8:00 AM EST - 5 months ago

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2025-11-12T14:15:25.000Z - 6 months ago

Lexaria Bioscience extends material transfer agreement with pharma company

2025-10-14T20:05:29.000Z - 7 months ago

Lexaria Bioscience files to sell 2.76M shares of common stock for holders

2025-10-09T13:25:23.000Z - 7 months ago

Lexaria Bioscience engages advisory firm to identify new business opportunities

Oct 9, 2025, 9:20 AM EDT - 7 months ago

Lexaria Bioscience Corp. Provides Strategic Update

Sep 29, 2025, 4:30 PM EDT - 8 months ago

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 26, 2025, 8:10 AM EDT - 8 months ago

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 19, 2025, 11:20 AM EDT - 8 months ago

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Aug 14, 2025, 9:20 AM EDT - 9 months ago

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Aug 6, 2025, 9:20 AM EDT - 10 months ago

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Jul 28, 2025, 9:25 AM EDT - 10 months ago

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Jul 23, 2025, 9:25 AM EDT - 10 months ago

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

May 12, 2025, 9:00 AM EDT - 1 year ago

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

Apr 28, 2025, 4:15 PM EDT - 1 year ago

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Apr 23, 2025, 9:10 AM EDT - 1 year ago

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Apr 3, 2025, 9:10 AM EDT - 1 year ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Apr 2, 2025, 9:05 AM EDT - 1 year ago

Lexaria's Human GLP-1 Study #5 Begins Dosing

Mar 18, 2025, 9:15 AM EDT - 1 year ago

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

Feb 27, 2025, 8:00 AM EST - 1 year ago

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Feb 24, 2025, 8:00 AM EST - 1 year ago

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Feb 20, 2025, 8:00 AM EST - 1 year ago

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Feb 11, 2025, 8:00 AM EST - 1 year ago

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Feb 6, 2025, 9:40 AM EST - 1 year ago

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Jan 15, 2025, 9:20 AM EST - 1 year ago

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Jan 14, 2025, 9:10 AM EST - 1 year ago

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Dec 19, 2024, 9:05 AM EST - 1 year ago

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Dec 18, 2024, 9:25 AM EST - 1 year ago

Lexaria Forms New Scientific Advisory Board

Dec 17, 2024, 9:10 AM EST - 1 year ago

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

The_Wealth_Maker May. 19 at 6:44 PM

$LEXX 'The only thing I know is that I know nothing.' - Socrate -

0 · Reply

Boston7452 May. 19 at 6:13 PM

0 · Reply

Bigfin May. 19 at 6:04 PM

0 · Reply

focafoca99 May. 19 at 4:42 PM

$LEXX eyes mid-June dosing after IRB approval for its new oral semaglutide pilot study.

0 · Reply

Boston7452 May. 19 at 4:25 PM

1 · Reply

Boston7452 May. 19 at 4:10 PM

1 · Reply

Makingmillions192 May. 19 at 3:26 PM

1 · Reply

Makingmillions192 May. 19 at 3:19 PM

0 · Reply

hovian May. 19 at 2:51 PM

$LEXX cant belive someone can get lexx shares at 55 cents...

0 · Reply

hovian May. 19 at 2:48 PM

$LEXX is this sp real? men I cant belive... how many shares have Bunka?

0 · Reply

Makingmillions192 May. 19 at 2:28 PM

$LEXX Imagine your stock losing half its market cap in under a month and the IR team not even taking 5 minutes to reach out to investors. Must be a hard life making hundreds of thousands of dollars and working 4 hours a week.

0 · Reply

Makingmillions192 May. 19 at 2:26 PM

$LEXX And why are they advertising on Prismmarketview? These guys have 700 subscribers 😂 I guess after paying Rich we couldn’t afford anything else.

0 · Reply

Makingmillions192 May. 19 at 2:20 PM

$LEXX Company where our current CEO came from. And we wonder why the stock is down 85% since he joined. Why the fuck are we paying this clown 600k a year. Bunka, pull your head out of your ass.

0 · Reply

Makingmillions192 May. 19 at 1:37 PM

$LEXX Free-Riding Partner: Why grant PharmaCO a zero-cost MTA extension? Retail bore 100% of the $15M R&D risk; why do they get a free ride to wait for data without an upfront option fee? The Tablet Pivot: Why ditch capsules to mimic Novo’s tablet tech just now? Does this mean previous capsule data was deemed commercially unviable by big pharma? Hypertension Abandonment: Why gamble all leverage on a single GLP-1 binary? Why isn't our advanced hypertension asset being shopped for a non-dilutive valuation floor? Success Metrics: What specific PK targets equal a "win"? If we only match Wegovy instead of beating it, what is the actual value? Scripted Avoidance: Why fund slick, scripted videos instead of an open Q&A call? Why hasn’t one insider bought shares?

1 · Reply

Makingmillions192 May. 19 at 1:28 PM

$LEXX Next reformulated series coming up on ethics approval 😂

1 · Reply

hovian May. 19 at 1:28 PM

$LEXX nice update add tomy hope ... will b waiting for results and JV

0 · Reply

Makingmillions192 May. 19 at 1:19 PM

$LEXX https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/lexaria-receives-independent-review-board-approval-to-begin-human-pilo-1167517

0 · Reply

Makingmillions192 May. 19 at 12:51 PM

$LEXX Has anyone heard from IR in the last month?

0 · Reply

Makingmillions192 May. 19 at 12:09 AM

$LEXX If they can deliver something tangible like either of these options than it’s a different ball game.

0 · Reply

TURNINGTHINGSAROUND May. 18 at 10:11 PM

$LEXX don’t trust Canadian small cap stocks. All fraud.

0 · Reply

TURNINGTHINGSAROUND May. 18 at 10:11 PM

$LEXX that’s why the owner gave his shares away. They are worth zero.

0 · Reply

harlem111 May. 18 at 8:58 PM

$LEXX Miracle would be If I get my money back!!!

0 · Reply

Market Cap	14.68M
Revenue (ttm)	710,000.00
Net Income (ttm)	-11.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,676.06%
Debt to Equity Ratio	0.00

Volume	70,499
Avg Vol	188,790
Day's Range	N/A - N/A
Shares Out	24.79M
Stochastic %K	6%
Beta	0.37
Analysts	Strong Sell
Price Target	$4.50